Galmed Pharmaceuticals (NASDAQ:GLMD) has been given a $14.00 price objective by Maxim Group in a research note issued on Wednesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price suggests a potential upside of 71.99% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. ValuEngine downgraded shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research downgraded shares of Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th. Roth Capital started coverage on shares of Galmed Pharmaceuticals in a research note on Wednesday, November 15th. They issued a “buy” rating and a $32.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Galmed Pharmaceuticals in a research note on Friday, November 10th. Finally, Seaport Global Securities reiterated a “buy” rating and issued a $19.00 target price on shares of Galmed Pharmaceuticals in a research note on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $18.30.

Galmed Pharmaceuticals (NASDAQ:GLMD) traded up $0.12 during midday trading on Wednesday, hitting $8.14. 142,689 shares of the company’s stock were exchanged, compared to its average volume of 35,535. Galmed Pharmaceuticals has a 12-month low of $3.04 and a 12-month high of $9.59.

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. KCG Holdings Inc. purchased a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 20,473 shares of the biopharmaceutical company’s stock, valued at approximately $100,000. KCG Holdings Inc. owned 0.17% of Galmed Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 9.85% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Galmed Pharmaceuticals (GLMD) Given a $14.00 Price Target by Maxim Group Analysts” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/12/06/galmed-pharmaceuticals-glmd-given-a-14-00-price-target-by-maxim-group-analysts.html.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.